NCT04923620View on ClinicalTrials.gov

Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy

RecruitingOBSERVATIONAL
Enrollment

51

Participants

Timeline

Start Date

October 20, 2021

Primary Completion Date

August 31, 2024

Study Completion Date

June 30, 2025

Conditions
Neoadjuvant TreatmentRectal CancerCetuximabRadiotherapy
Interventions
DRUG

cetuximab+mFOLFOX6

cetuximab 500mg/m2 d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles

RADIATION

short-course radiotherapy

25Gy/5Fx short-course radiotherapy between the forth and the fifth cycle of cetuximab+mFOLFOX6

Trial Locations (1)

200020

RECRUITING

Ruijin Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Minimally Invasive Surgery Center

OTHER